SecBot SecBot
SECBOTREPLAY Home › Report › BVS

BVS · Bioventus (BVS) reported Q1 2026 EPS of $0.15, a 30.6% miss versus the…

Bioventus, Inc. · PRESS-RELEASE filed Jun 2, 2026 at 07:00 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Jun 2, 2026 at 07:00 ET

Bioventus (BVS) reported Q1 2026 EPS of $0.15, a 30.6% miss versus the $0.22 consensus, on revenue of $155.4M (in line with the $155.4M estimate). The press release focuses on an upcoming conference appearance, not guidance or operational details, leaving the miss as the primary takeaway.

  • Q1 2026 EPS of $0.15 missed consensus of $0.22 by 30.6%
  • Revenue of $155.4M was in line with consensus of $155.4M
  • No guidance update or operational commentary provided in the release
  • CFO to present at Goldman Sachs Global Healthcare Conference on June 8, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access